Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Am J Ophthalmol. 2019 Jun 8;207:77–86. doi: 10.1016/j.ajo.2019.06.002

Table 1.

Clinical characterization of the female choroideremia carriers.

Patient ID Age at Presentation (yr) Age of Onset (yr) BCVA (OD; OS) Severity of disease Reason for referral Other Medical History Family History of Choroideremia
1 23 20s 20/20; 20/30 Severe Retinal evaluation IDH2 brain glioma s/p resection No
2 76 40s 20/30; 20/40 Severe Retinitis pigmentosa n/c No
3 60 30s 20/70; 20/60 Severe Choroideremia carrier n/c Yes: father, grandson, paternal uncle
4 61 30s 20/150; HM Severe Macular degeneration n/c No
5 77 60s 20/30; 20/60 Intermediate Findings of
RPE atrophy
n/c Yes: son
6 64 60s 20/25; 20/40 Intermediate Retinal evaluation Diabetic retinopathy, s/p PRP Yes: father, male cousin
7 63 n/a 20/25; 20/25 Intermediate Asymptomatic screen n/c Yes: son, father
8 50 n/a 20/20; 20/20 Intermediate Asymptomatic screen n/c Yes: son
9 68 60s 20/20; 20/20 Mild Macular degeneration n/c Yes: son
10 29 20s 20/20; 20/25 Mild Retinitis pigmentosa n/c Yes: 2 brothers, 3 maternal uncles
11 53 n/a 20/40; 20/40 Mild Asymptomatic screen n/c Yes: son, brother
12 51 n/a 20/20; 20/20 Mild Asymptomatic screen n/c Yes: son

BCVA = best-corrected visual acuity; HM = hand motion; IDH2 = isocitrate dehydrogenase 2; n/a = nonapplicable; n/c = non-contributory; PRP = panretinal photocoagulation; RPE = retinal pigment epithelium.